Skip to content

Jobs updated Oct 23, 6:25 AM CT

COMPANY

Persevere Therapeutics

perseveretherapeutics.com ↗

Clinical Phase 1

Profile checked Oct 10, 2026

Keywords: Ovarian Cancer misetionamide (also known as GP-2250)

1Trials (company is sponsor)

Timeline

Mar 3, 2026 Raise Private equity round — Seed: amount not published, announced Mar 3, 2026. Source: company's own press page. source ↗ · Form D filed Mar 4, 2026 SEC Form D ↗
Jan 14, 2019 Trial start Phase 1: A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine source ↗

Upcoming milestones

Jul 31, 2027 (ESTIMATED) · Phase 1 · A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine · NCT03854110

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: amount not published. Last 2 years.

Mar 3, 2026 Private equity round — Seed: amount not published, announced Mar 3, 2026. Source: company's own press page. source ↗ · Form D filed Mar 4, 2026 SEC Form D ↗

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT03854110	A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine	Phase 1	Recruiting	Jan 14, 2019	Jul 31, 2027 (estimated)